DelveInsight’s “Multiple Myeloma Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Multiple Myeloma pipeline landscapes.
The report comprises Multiple Myeloma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Multiple Myeloma pipeline products.
Some of the key takeaways from the Multiple Myeloma Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen Research & Development, Regeneron Pharmaceuticals, Bristol-Myers Squibb/Celgene, BMS/ AstraZeneca, Pfizer (Array Biopharma), BioLineRx, MorphoSys AG/I-Mab Biopharma, Chipscreen Biosciences, etc., are developing therapies for the treatment of Multiple Myeloma.
-
Emerging therapies such as Descartes-11, Venetoclax, Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), Keytruda (Pembrolizumab), Cetrelimab (JNJ-63723283), REGN5458, Iberdomide, Imfinzi (Durvalumab; MEDI4736), Braftovi (encorafenib), Motixafortide (BL-8040), Felzartamab (MOR202), Chidamide (Epidaza), are expected to have a significant impact on the Multiple Myeloma market in the coming years.
Get an overview of pipeline landscape @ Multiple Myeloma Clinical Trials Analysis
Multiple myeloma is a cancer of plasma cells. In general, when plasma cells grow to be cancerous and develop out of manipulating, that is known as multiple myeloma. The plasma cells make an ordinary protein acknowledged through several extraordinary names, together with monoclonal immunoglobulin, monoclonal protein (m-protein), m-spike, or paraprotein. Regular plasma cells are determined within the bone marrow and are an enormous part of the immune device.
Multiple Myeloma Pipeline Therapies along with Key Players:
-
Descartes-11 by Cartesian Therapeutics
-
Venetoclax by AbbVie and Roche
-
Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M) by Janssen Biotech/Nanjing Legend Biotech
-
Keytruda (Pembrolizumab) by Merck Sharp & Dohme Corp.
-
Cetrelimab (JNJ-63723283) by Janssen Research & Development
-
REGN5458 by Regeneron Pharmaceuticals
-
Iberdomide by Bristol-Myers Squibb/Celgene
-
Imfinzi (Durvalumab; MEDI4736) by BMS/ AstraZeneca
-
Braftovi (encorafenib) by Pfizer (Array Biopharma)
-
Motixafortide (BL-8040) by BioLineRx
-
Felzartamab (MOR202) by MorphoSys AG/I-Mab Biopharma
-
Chidamide (Epidaza) by Chipscreen Biosciences
-
And others.
Scope of Multiple Myeloma Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen Research & Development, Regeneron Pharmaceuticals, Bristol-Myers Squibb/Celgene, BMS/ AstraZeneca, Pfizer (Array Biopharma), BioLineRx, MorphoSys AG/I-Mab Biopharma, Chipscreen Biosciences, and others.
-
Pipeline Therapies: Descartes-11, Venetoclax, Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), Keytruda (Pembrolizumab), Cetrelimab (JNJ-63723283), REGN5458, Iberdomide, Imfinzi (Durvalumab; MEDI4736), Braftovi (encorafenib), Motixafortide (BL-8040), Felzartamab (MOR202), Chidamide (Epidaza), and others.
Table of Contents
|
1 |
Multiple Myeloma Report Introduction |
|
2 |
Multiple Myeloma Executive Summary |
|
3 |
Multiple Myeloma Overview |
|
4 |
Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Multiple Myeloma Pipeline Therapeutics |
|
6 |
Multiple Myeloma Late Stage Products (Phase II/III) |
|
7 |
Multiple Myeloma Mid Stage Products (Phase II) |
|
8 |
Multiple Myeloma Early Stage Products (Phase I) |
|
9 |
Multiple Myeloma Preclinical Stage Products |
|
10 |
Multiple Myeloma Therapeutics Assessment |
|
11 |
Multiple Myeloma Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Multiple Myeloma Key Companies |
|
14 |
Multiple Myeloma Key Products |
|
15 |
Multiple Myeloma Unmet Needs |
|
16 |
Multiple Myeloma Market Drivers and Barriers |
|
17 |
Multiple Myeloma Future Perspectives and Conclusion |
|
18 |
Multiple Myeloma Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.
DelveInsight’s Multiple Myeloma – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/